Lenalidomide Efficacy and safety in non-del 5q MDS Patients

A total of 93 patients (43%) responded to lenalidomide treatment according to the modified IWG 2000 criteria. A total of 56 (26%) patients achieved RBC TI with a concurrent 10 g/L (1 g/dL) or higher peak rise in hemoglobin; 37 (17%) patients had a 50% or greater reduction in transfusions. There was no significant difference in response rate according to assigned treatment schedule (*P*=.876).

Treatment-associated adverse events (≥10%)

	Lenalidomide dose					
	Continuous daily dosing (n=100)		21-day dosing (n=114)		All patients (n=214)	
Adverse event	Any grade	Grade 3 or 4	Any grade	Grade 3 or 4	Any grade	Grade 3 or 4
Neutropenia	30	27	26	23	28	25
Thrombocytopenia	31	22	22	18	26	20
Rash	24	2	20	6	22	4
Pruritus	21	1	21	1	21	1
Constipation	17	0	13	1	15	1
Diarrhea	16	1	13	1	15	1
Fatigue	18	4	13	4	15	4
Peripheral edema	3	0	16	1	10	1
Nausea	11	2	6	0	8	1

- Data are percentages.